Attention deficit hyperactivity disorder. Narcolepsy.
Individualize. Narcolepsy: 5–60mg daily in divided doses.
Individualize. ADHD: <6yrs: not recommended. ≥6yrs: initially 5mg 1–2 times daily; may increase by 5mg/day at weekly intervals; usual max 40mg/day. Narcolepsy: 6–12yrs: initially 5mg daily; may increase by 5mg/day at weekly intervals. ≥12yrs: initially 10mg daily; may increase by 10mg/day at weekly intervals.
Cardiovascular disease. Hypertension. Arteriosclerosis. Hyperthyroidism. Glaucoma. Drug or alcohol abuse. Agitation. During or within 14 days of MAOIs. Hypersensitivity to sympathomimetics.
High abuse potential. Structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease: not recommended. Hypertension. Heart failure. Recent MI. Arrhythmia. Assess cardiovascular status prior to treatment. Tourette's syndrome. Psychosis. Bipolar disorder. Monitor for worsening of aggressive behavior or hostility. Seizure disorder; discontinue if occur. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth, blood pressure, heart rate, vision. Prescribe limited supply to minimize overdose. Reevaluate need for therapy after drug-free interval. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Hypertensive crisis with MAOIs. Potentiated by alkalinizers, MAOIs, propoxyphene (can cause convulsions), furazolidone. Potentiates tricyclic antidepressants, sympathomimetics, meperidine, norepinephrine, phenobarbital, phenytoin. Antagonized by acidifiers, chlorpromazine, haloperidol, lithium, methenamine. Antagonizes adrenergic blockers, ethosuximide, antihypertensives, sedating antihistamines, veratrum alkaloids. May interfere with urinary steroid tests.
Palpitations, hypertension, tachycardia, CNS overstimulation, dizziness, insomnia, headache, motor and phonic tics, dry mouth, GI disorders, anorexia, urticaria, impotence; visual disturbances, Tourette's syndrome.